Under the terms of the agreement, mAbxience, a Fresenius Kabi majority-owned group [1], will manufacture the biosimilars in their state-of-the art and good manufacturing practices (GMP)-approved facilities in Spain and Argentina. mAbxience will also be responsible for driving the clinical milestones for some of the molecules still undergoing development. The biosimilars, focusing on oncology, women’s health and respiratory disease, will be commercialized by Abbott. This will occur in the emerging markets of Latin America, Southeast Asia, the Middle East, and Africa.

This new agreement expands on that initiated in 2018, whereby the two companies were able to provide various treatment options for two oncology biosimilars in countries across Latin America including Columbia, Chile, Peru and various countries in Central America. First molecules expected to launch as early as 2025, offering new treatment options that leverage the latest in scientific breakthroughs for people in emerging markets.

mAbxience has entered other such partnerships to broaden its reach globally. For example, they have entered a partnership with HK inno.N in South Korea, to commercialise a denosumab biosimilar [2].

Related article
Fresenius Kabi signs marketing agreement for adalimumab biosimilar

References
1. GaBI Online - Generics and Biosimilars Initiative. Fresenius Kabi acquire mAbxience and Ivenix [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Nov 14]. Available from: www.gabionline.net/pharma-news/fresenius-kabi-acquire-mabxience-and-ivenix
2. GaBI Online - Generics and Biosimilars Initiative. HK inno.N–mAbxience partnership in Korea and Coherus advances in the US[www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Nov 14]. Available from: www.gabionline.net/pharma-news/hk-inno.n-mabxience-partnership-in-korea-and-coherus-advances-in-the-us

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2023 Pro Pharma Communications International. All Rights Reserved.